Actuate Therapeutics (NASDAQ:ACTU) CEO Purchases $49,295.40 in Stock

Actuate Therapeutics, Inc. (NASDAQ:ACTU) CEO Daniel Schmitt acquired 140,844 shares of the stock in a transaction that occurred on Wednesday, October 28th. The stock was purchased at an average price of $0.35 per share, for a total transaction of $49,295.40. Following the completion of the acquisition, the chief executive officer owned 442,560 shares in the company, valued at $154,896. The trade was a 46.68% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Actuate Therapeutics Trading Down 9.7%

NASDAQ:ACTU opened at $0.34 on Friday. Actuate Therapeutics, Inc. has a 12 month low of $0.33 and a 12 month high of $7.90. The stock has a 50 day moving average of $0.90 and a two-hundred day moving average of $2.18. The firm has a market cap of $8.05 million, a P/E ratio of -0.39 and a beta of 1.20.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. On average, research analysts forecast that Actuate Therapeutics, Inc. will post -0.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

ACTU has been the subject of several recent research reports. Rodman & Renshaw began coverage on Actuate Therapeutics in a research note on Thursday, July 30th. They issued a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, September 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Actuate Therapeutics in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. ABS Direct Equity Fund LLC grew its position in shares of Actuate Therapeutics by 46.4% in the second quarter. ABS Direct Equity Fund LLC now owns 73,186 shares of the company’s stock valued at $112,000 after purchasing an additional 23,186 shares in the last quarter. HighTower Advisors LLC purchased a new position in Actuate Therapeutics during the second quarter worth approximately $56,000. Susquehanna International Group LLP purchased a new position in Actuate Therapeutics during the second quarter worth approximately $43,000. Palogic Value Management L.P. acquired a new position in Actuate Therapeutics during the second quarter worth $153,000. Finally, ABS Investment Management LLC acquired a new position in Actuate Therapeutics during the second quarter worth $111,975.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s lead product candidate is elraglusib, an investigational small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), an enzyme involved in tumor growth, inflammation and immune regulation.

Actuate is evaluating elraglusib in clinical studies involving hematologic malignancies and solid tumors, including acute myeloid leukemia, pancreatic cancer and other difficult-to-treat cancers.